(nevirapine), Valtrex (valacyclovir),
Zmax (azithromycin), Rotarix (rotavirus
vaccine, live, oral), Kinrix (Diphtheria
and Tetanus Toxoids and Acellular
Pertussis Adsorbed and Inactivated
Poliovirus Vaccine), Pentacel
(Diphtheria and Tetanus Toxoids and
Acellular Pertussis Adsorbed,
Inactivated Poliovirus and Haemophilus
b Conjugate [Tetanus Toxoid Conjugate
Vaccine], and Daptacel (Diphtheria and
Tetanus Toxoids and Acellular Pertussis
Vaccine Adsorbed vaccine). The
committee will also receive an update
on Topical Calcineurin Inhibitors: Elidel
(pimecrolimus) and Protopic
(tacrolimus). Also, the committee will
receive a brief followup on the FDA
Early Communication about reports of
liver-related adverse events in patients
taking orlistat (marketed as Alli and
Xenical).

FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at http://www.fda.gov/Advisory
Committees/Calendar/default.htm. Scroll down to the
appropriate advisory committee link.

Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before March 8, 2010. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Those desiring to make
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before February 28, 2010. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
March 1, 2010.

Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.

FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort
to accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Doreen
Kezer, at least 7 days in advance of the
meeting.

FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
http://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.

Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).

Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.

[FR Doc. 2010–3024 Filed 2–17–10; 8:45 am]
BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Centers for Disease Control and
Prevention

Breast and Cervical Cancer Early
Detection and Control Advisory
Committee (BCCEDCAC)

In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following committee
meeting:

Times and Dates: 12 p.m.–5 p.m., March
15, 2010, 8:30 a.m.–5 p.m., March 16, 2010,
8:30 a.m.–3 p.m., March 17, 2010.
Place: Crowne Plaza Atlanta Perimeter at
Ravinia, 4355 Ashford Dunwoody Road,
Atlanta, GA 30346, Telephone: 770–395–
7700.
Status: Open to the public, limited only by
the number of seats available.
Purpose: The committee is charged with
advising the Secretary, Department of Health
and Human Services, and the Director, CDC,
regarding the early detection and control
of breast and cervical cancer. The committee
makes recommendations regarding national
program goals and objectives;
implementation strategies; and program
priorities including surveillance,
epidemiologic investigations, education and
training, information dissemination,
professional interactions and collaborations,
and policy.

Matters To Be Discussed: The agenda will
include discussion and review of U.S.
Preventive Services Task Force guidelines for
breast and cervical cancer screening; Impact
of the revised clinical screening
recommendations for both breast and cervical
cancer on the National Breast and Cervical
Cancer Early Detection Program; Discussion
of what, if any, modifications should be
made to the NBCCEDP’s current screening
policies based on revised recommendations.
Agenda items are subject to change as
priorities dictate.

Contact Person for More Information: Dr.
Chastity Walker, Designated Federal Officer,
BCCEDCAC, Division of Cancer Prevention
and Control, National Center for Chronic
Disease Prevention and Health Promotion,
CDC, 4770 Buford Highway, Mailstop K–57,
Chamblee, Georgia 30316, Telephone: 770–
488–3013.

The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.

[FR Doc. 2010–3143 Filed 2–17–10; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2010–N–0001]

Circulatory System Devices Panel of
the Medical Devices Advisory
Committee; Notice of Meeting

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice.

This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
Public.

Name of Committee: Circulatory System
Devices Panel of the Medical Devices
Advisory Committee.

General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.

Date and Time: The meeting will be
held on March 18 and 19, 2010, from 8
a.m. to 6 p.m.

Location: College Park Holiday Inn,
Grand Ballroom, 10000 Baltimore Ave.,
College Park, MD.

Contact Person: James Swink, Center
for Devices and Radiological Health.

Food and Drug Administration, 10903
New Hampshire Ave., Silver Spring, MD